 | | Vol. 5.07 – 26 February, 2021 |
| |
|
|
| Researchers systematically addressed fundamental questions about the source of new liver cells by generating a panel of 11 new CreER knock-in mouse models that labeled zonal subpopulations across the liver lobule.
[Science] |
|  |
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| In hepatocellular carcinoma cell lines, laminin γ2 monomer was expressed in alpha‐fetoprotein‐negative cluster of differentiation 90‐positive cells characterized by highly metastatic natures.
[Hepatology] |
|
|
|
| In vitro analysis demonstrated that myofibroblasts promoted cell proliferation, invasion, and epithelial‐mesenchymal transformation of hepatocellular carcionoma cells, whereas Musashi RNA binding protein 2 (Msi2) deletion in myofibroblasts reversed these effects.
[Hepatology] |
|
|
|
| The authors reported the novel of tumor cell-expressed Piwi Like RNA-Mediated Gene Silencing 1 (PIWIL1) in mediating the crosstalk of fatty acid metabolism and immune response of human hepatocellular carcinoma.
[Signal Transduction and Targeted Therapy] |
|
|
|
| Scientists report that HDAC11 was highly expressed in hepatocellular carcinoma and was closely related to disease prognosis. Depletion of HDAC11 in a conditional knockout mouse model reduced hepatocellular tumorigenesis and prolonged survival.
[Cancer Research] |
|
|
|
| Researchers uncovered a TNFR2-hnRNPK-YAP signaling axis in hepatic progenitor cells essential for primary liver cancer development.
[Cancer Research] |
|
|
|
| Scientists investigated differences in cellular architecture as a function of cell culture system, using confocal scanning laser microscopy, and determined differences in binding interactions between hepatitis C virus virus-like particles and their cognate receptors in the different cell culture systems using atomic force microscopy.
[Journal of Colloid and interface Science] |
|
|
|
| Researchers investigated the expression of TGFβ signaling in c-MYC amplified human hepatocellular carcinoma samples as well as the mechanisms whereby TGFβ modulated c-Myc driven hepatocarcinogenesis during initiation and progression.
[Cell Death & Disease] |
|
|
|
| The authors used rat liver-derived hepatocytes injured by CCl4 treatment in co-culture system with Vitamin E pretreated-Wharton’s jelly-derived MSCs (WJMSCs) to evaluate the hepatoprotective effect of vitamin E-WJMSCs.
[Biochemical Pharmacology] |
|
|
|
| Researchers showed that in hepatocellular carcinoma tumors the highest expression level of HK2 was inversely correlated to GCK expression, and was associated to poor prognosis for patient survival.
[Communications Biology] |
|
|
|
| The effects of lactonic sophorolipids and cell death inhibitors were measured by MTT test on HepG2 cells. Their morphology of the cells was observed under a microscope.
[Applied Microbiology and Biotechnology] |
|
|
|
| To mimic liver fibrosis in vitro, LX-2 cells were treated with TGF-β. Gene and protein expressions were detected by RT-qPCR and western blot, respectively.
[Human Cell] |
|
|
|
| The recovery of C2orf40 expression in hepatocellular carcinoma cell lines could induce G0/G1 phase arrest and apoptosis, and also inhibit cell migration and invasion by reversing the epithelial–mesenchymal transition process, both in vivo and in vitro.
[Journal of Gastroenterology and Hepatology] |
|  |
|
|
|
| The authors summarize findings indicating that the dysregulation of stress kinases plays a fundamental role in the development of steatosis and are important players inducing liver fibrosis.
[Molecular Metabolism] |
|
|
|
| Investigators discuss the role of platelets in liver fibrosis and accompanying hemostatic disorders. They present the results of animal and human studies on antiplatelet drugs in liver disorders and their potential therapeutic utility.
[Platelets] |
|
|
|
|
| Can-Fite BioPharma Ltd. announced new data from the Phase II advanced liver cancer study including overall survival of nearly four years in two patients who are under namodenoson treatment.
[Can-Fite BioPharma Ltd.] |
|
|
|
| Arch Biopartners, Inc. announced that the Peter Lougheed Center in Calgary, Alberta has joined the Phase II trial of its lead drug LSALT peptide, targeting the prevention of acute lung injury, acute kidney injury, and other complications caused by inflammation in hospitalized patients with moderate to severe cases of COVID-19.
[Arch Biopartners, Inc.] |
|
|
|
|
| September 5 – 8, 2021
Exeter, England, United Kingdom |
|
|
|
|
|
| | Cancer Research Center of Lyon – Lyon, France |
|
|
|
| | CyberCoders – San Diego, California, United States |
|
|
|
| | Gilead Sciences, Inc. – Foster City, California, United States |
|
|
|
| | The Francis Crick Institute – London, England, United Kingdom |
|
|
|
| | Baylor College of Medicine – Houston, Texas, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
